MedCity News
MARCH 14, 2023
Novo Nordisk can afford the price cuts prices to several branded and non-branded insulins. Flattening revenue for the pharmaceutical giant’s insulin products is offset by demand for diabetes and obesity drugs from its semaglutide franchise, which continues to grow by leaps and bounds.
Fierce Pharma
MARCH 16, 2023
AstraZeneca employees fight layoffs in India as drugmaker shifts 'strategic priorities' aliu Thu, 03/16/2023 - 09:54
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MARCH 16, 2023
Earlier this week, the Florida Senate advanced a bill to restrict gender-affirming care for transgender minors. The bill is one of many that are currently being discussed in different states. Many politicians have cited doubts about the potential “harm” caused by puberty blockers and hormone therapies associated with gender-affirming care and concerns about incorrect treatment as major factors.
European Pharmaceutical Review
MARCH 15, 2023
The latest version of software tool MZmine, which aids analysis of mass spectrometry data, has been released. Using this third generation software, scientists can analyse large volumes of data from mass spectrometry, processing thousands of samples within minutes to hours. [the newest version can process] thousands of samples within minutes to hours.” It is the first tool with an entire data processing pipeline that integrates liquid chromatography (LC)-ion mobility spectrometry (IMS)-MS a
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
.png)
Medgadget
MARCH 17, 2023
Researchers at Linköping University in Sweden have developed a method whereby the body can ‘grow its own’ electrodes. The minimally invasive technique involves injecting a hydrogel that is laden with enzymes into target tissues. The enzymes interact with molecules that are present in the tissue to change the structure of the gel and allow it to become electrically conductive.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
MARCH 16, 2023
Royalty Pharma’s milestone payment from the approval of Pfizer migraine drug Zavzpret stems from financing deals struck with the therapy’s previous developer, Biohaven Pharmaceuticals. Royalty Pharma is also in line to receive royalty payments going beyond the next decade.
Impetus Digital
MARCH 14, 2023
This is a guest article written by Luke Buchanan, CEO of Redi.Health , and does not necessarily reflect the views and values of Impetus Digital. When we think of adherence in the medical world, it’s often simplified to something along the lines of the degree to which a patient correctly follows medical advice. It’s a simple statement with many, many moving parts, especially when we’re talking about patients with multiple chronic conditions.
Pharmaceutical Technology
MARCH 17, 2023
As the field of digital therapeutics continues to broaden, specific uses in mental health and neurology are increasingly making headway for patients and on the market. At the same time, experts are saying developers in the field need to double down on securing clinical data to allow for its continued maturation. Companies are testing the use of digital platforms along with pharmacological treatments.
Fierce Pharma
MARCH 17, 2023
Astellas, Pfizer look to broaden Xtandi’s patient base with new prostate cancer win after 8 years aliu Fri, 03/17/2023 - 10:22
MedCity News
MARCH 17, 2023
Without a new set of tools that clinicians can access at the point of care, the availability of information from QHINs will increase provider burdens because they will struggle to find the information needed to evaluate a patient, take action, complete documentation, and move to the next patient.
Modus
MARCH 16, 2023
There's a paradigm shift in sales enablement. More than ever before, sellers and marketers are struggling to: ✔️ Engage buyers. ✔️ Maximize content usage. ✔️ Optimize selling time. ✔️ And achieve ROI.
Pharmaceutical Technology
MARCH 17, 2023
Pharmanovia and Aeterna Zentaris have entered an exclusive licensing agreement for the latter’s medicine Ghryvelin (macimorelin). Under the deal, Pharmanovia will acquire the exclusive rights and license to commercialise Ghryvelin in the EEA and the UK from Consilient Health. Ghryvelin is used for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare and serious condition, as well as for Childhood Onset Growth Hormone Deficiency (CGHD), if approved.
Fierce Pharma
MARCH 13, 2023
With $43B buyout, Pfizer sees cancer specialist Seagen as a 'goose' laying 'golden eggs' kdunleavy Mon, 03/13/2023 - 10:16
MedCity News
MARCH 15, 2023
Already, ChatGPT has been named as a co-author on at least four research papers. With proper management, AI generation could be an invaluable tool in clinical research—but only if we are mindful of the potential risks and biases that may arise from their usage and ensure transparency, fairness, and accountability in their use.
European Pharmaceutical Review
MARCH 14, 2023
Pfizer has announced it will acquire Seagen Inc. for a total enterprise value of $43 billion. “Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining Seagen’s antibody -drug conjugate (ADC) technology… with Pfizer’s capabilities and expertise,” shared Dr Albert Bourla, Pfizer Chairman and Chief Executive Officer.
Pharmaceutical Technology
MARCH 16, 2023
Talem Therapeutics, a subsidiary of Immunoprecise Antibodies, has entered a multi-target artificial intelligence (AI)-driven antibody discovery collaboration with Libera Bio. The partnership will use nanotechnology, which was proven in vivo, for providing antibodies inside tumour cells and provides a potential solution to address the medical challenge.
Fierce Pharma
MARCH 15, 2023
AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate kdunleavy Wed, 03/15/2023 - 10:09
MedCity News
MARCH 17, 2023
Perspectum — a company that makes medical imaging devices designed to improve the diagnosis of metabolic diseases and cancer — recently announced the second close of its $55 million Series C funding round. Its flagship product is a diagnostic tool that assesses and monitors chronic liver disease.
Medgadget
MARCH 17, 2023
Researchers at Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland have developed a method to 3D print mineralized constructs with a little helping hand from bacteria. The technique consists of printing a polymer bioink that contains bacteria that will produce calcium carbonate when exposed to a urea solution. The two-step process also involves printing a construct and then exposing it to urea for several days, over which time the bacteria naturally mineralize the structure.
Pharmaceutical Technology
MARCH 14, 2023
The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda ’s dengue virus vaccine candidate, Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). The vaccine has received approval for preventing dengue disease in people aged four years to 60 years. Qdenga has been developed based on a live-attenuated dengue serotype 2 virus that offers the genetic backbone for four dengue virus serotypes and is designed to provide protection against any of these.
Fierce Pharma
MARCH 14, 2023
Novo Nordisk follows Eli Lilly's lead, slashing insulin prices in the US kdunleavy Tue, 03/14/2023 - 10:56
MedCity News
MARCH 16, 2023
Some actions to reduce healthcare’s carbon footprint actually will save money, said Jonathan Perlin, CEO of the nonprofit national and international accrediting organization.
European Pharmaceutical Review
MARCH 17, 2023
In a first-of-its-kind commercial agreement, Great Ormond Street Hospital NHS Foundation Trust (GOSH) will work with Leucid Bio to manufacture LEU011, a lateral Chimeric Antigen Receptor (CAR) targeting NKG2D ligands. The CAR T therapy will be used in clinical studies for solid tumours and haematological malignancies. Under the agreement the parties will work together at state-of-the-art cleanroom facilities at the Zayed Centre for Research into Rare Disease in Children.
Pharmaceutical Technology
MARCH 17, 2023
Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic. These agreements have been particularly propelled by the recent rise in inflationary pressures and pharmaceutical market instability, pushing healthcare systems to find new ways to reduce risks associated with new drugs.
Fierce Pharma
MARCH 17, 2023
Sanofi answers the call, joining Eli Lilly, Novo Nordisk in cutting insulin prices kdunleavy Fri, 03/17/2023 - 09:07
MedCity News
MARCH 17, 2023
CMS should honor its commitment to Medicare beneficiaries, especially those who began home respiratory therapy under the PHE, without requiring them to “restart” the documentation process. Requiring requalification would also be a nightmare for physicians who are already overwhelmed with patient demands.
Evolve Your Success
MARCH 14, 2023
They say luck is what happens when preparation meets opportunities. Daniel Tighe ’s enterprising story is a great example of how one can thrive under these circumstances. In this episode, he joins Samuel Adeyinka to share with us how he has been able to generate more business and become more successful in spine distributorship. He tells his entrepreneurial origin, shedding light on how he tackled the opportunities that came his way and approached marketing.
Pharmaceutical Technology
MARCH 17, 2023
The Lung Cancer Research Foundation (LCRF) has announced a new research partnership with Daiichi Sankyo and AstraZeneca. This collaboration is intended to fund up to three research grants that are focused on antibody-drug conjugates (ADCs) for improving the outcomes for lung cancer patients. ADCs are designed for targeting cancer cells specifically and selectively provide a highly potent payload that may limit healthy cells’ damage.
Fierce Pharma
MARCH 15, 2023
Pfizer adjusts EU vaccine deal but still wants payment for undelivered doses: FT esagonowsky Wed, 03/15/2023 - 08:43
MedCity News
MARCH 13, 2023
AHIP and several other healthcare organizations launched the Connecting to Coverage Coalition last week in an effort to make the upcoming Medicaid redetermination process run smoothly. The coalition’s website includes studies on Medicaid redeterminations and frequently asked questions for enrollees. AHIP also released a report that shows 53.6% of those who will lose coverage will transition to employer-sponsored insurance and 21.2% will become uninsured.
InCrowd
MARCH 15, 2023
Deborah Dropcho, PA After initial introductions with my new PA students, I always present them with my opening question. “What is the single greatest thing you can provide your patients?” Answers range from basic to insightful. Compassion and advocacy are two that I now hear often. The answer I am looking for is quite simple; Education. I tell both patients and students alike that if a health care provider does not educate their patients about lifestyle modifications; they are doing them a disse
Legacy MEDSearch
MARCH 15, 2023
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced the strategic acquisition of substantially all assets from LIVMOR, a digital health solutions company providing a patient-engaging remote monitoring system of critical physiological biomarkers.
Fierce Pharma
MARCH 16, 2023
Pfizer's Paxlovid gets thumbs-up for full approval from FDA advisory committee kdunleavy Thu, 03/16/2023 - 16:46
Expert insights. Personalized for you.
98 
Let's personalize your content